Your browser is no longer supported. Please, upgrade your browser.
BNTC Benitec Biopharma Limited daily Stock Chart
Benitec Biopharma Limited
Index- P/E- EPS (ttm)-1.56 Insider Own- Shs Outstand146.53M Perf Week46.27%
Market Cap345.08M Forward P/E- EPS next Y- Insider Trans- Shs Float5.64M Perf Month69.42%
Income- PEG- EPS next Q- Inst Own- Short Float0.16% Perf Quarter66.90%
Sales7.02M P/S49.15 EPS this Y- Inst Trans- Short Ratio0.05 Perf Half Y39.35%
Book/sh2.00 P/B1.18 EPS next Y- ROA- Target Price14.00 Perf Year-40.08%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.20 - 4.40 Perf YTD53.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.13% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low79.17% ATR0.32
Employees- Current Ratio- Sales Q/Q2456.20% Oper. Margin- RSI (14)59.93 Volatility31.90% 11.61%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.12 Prev Close2.36
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume166.45K Price2.15
Recom3.00 SMA2030.34% SMA5037.23% SMA20037.67% Volume17,604 Change-8.70%
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Jan-18-17 09:30AM  Biotech Industry Outperforming Markets in 2017: Latest Reports on Benitec Biopharma and Tandem Diabetes Care Accesswire -21.50%
08:26AM  Benitec Stock Up on Orphan Drug Status for BB-301 in EU
08:15AM  Blog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy Accesswire
Jan-17-17 11:05AM  Tuesdays Top Biopharma Movers +62.16%
05:00AM  Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy PR Newswire
Dec-23-16 06:00AM  Benitec in-licenses clinical program for head and neck cancer from NantWorks PR Newswire
Dec-20-16 07:00AM  Benitec releases pivotal data in an in vivo hepatitis B model PR Newswire +9.54%
Oct-24-16 07:10PM  Benitec initiates a strategic engagement with NantVentures Other +26.24%
Sep-23-16 11:34AM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2016 By the Numbers : September 23, 2016
Aug-10-16 05:00AM  Benitec announces restructuring of Senior Executive team PR Newswire
May-24-16 04:45AM  Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016 PR Newswire
May-17-16 05:00AM  Benitec Biopharma to Host Corporate Update Conference Call PR Newswire
Apr-25-16 08:30AM  Benitec to present at the ASGCT 2016 Annual Meeting PR Newswire
Mar-08-16 08:16AM  Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo PR Newswire +15.88%
Mar-07-16 02:29PM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended December 31, 2015
Feb-26-16 07:26AM  Benitec Biopharma downgraded by Maxim Group -55.14%
Feb-25-16 10:13PM  Benitec Biopharma Limited: Interim Report for the Half Year Ended December 31, 2015 PR Newswire
06:42PM  Update on TT-034 Hepatitis C Clinical Trial PR Newswire
Jan-29-16 07:36PM  Appendix 4C - quarterly Other
Dec-10-15 07:51PM  Benitec Biopharma to Host Corporate Update Conference Call PR Newswire
Dec-08-15 05:05PM  Greg West, Benitec's Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer PR Newswire -6.43%
Dec-07-15 08:00AM  Benitec's Hepatitis B Therapeutic Shows Positive Preclinical Results PR Newswire +11.98%
Oct-29-15 11:13AM  Why the Australian Dollar Fell on Weak Inflation
Oct-22-15 08:00AM  Benitec Biopharma's Abstract Accepted for Presentation at the AASLD Liver Meeting 2015 PR Newswire +12.01%
Oct-19-15 07:30AM  Benitec Forms Hepatology Clinical Advisory Board Other
Oct-14-15 08:00AM  Benitec Biopharma to Present at The 14th Annual BIO Investor Forum Other
Oct-07-15 07:00AM  Lonza and Benitec Enter Agreement to Develop Scalable AAV Manufacturing Process for ddRNAi Therapeutics PR Newswire
Sep-25-15 10:23AM  Benitec Biopharma rings Nasdaq opening bell at CNBC
Sep-24-15 10:00AM  Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Sep-23-15 08:00AM  Benitec Featured at CHI's "Discovery On Target" Conference PR Newswire
Sep-16-15 07:30AM  Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial PR Newswire
Aug-24-15 07:30AM  Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ PR Newswire
Aug-05-15 02:45PM  IPO Outlook: Planet Fitness Bargain Gym Memberships Growing Strong +8.91%
Developing gene therapies for hepatitis C based on RNA interference.